{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:51:52Z","timestamp":1791647512874,"version":"4.3.4"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.iac.2022.10.005","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T18:15:45Z","timestamp":1688148945000},"page":"473-489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Drug Hypersensitivity Reactions"],"prefix":"10.1016","volume":"43","author":[{"given":"R. Gentry","family":"Wilkerson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2022.10.005_bib1","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies","volume":"279","author":"Lazarou","year":"1998","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.iac.2022.10.005_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2013.08.016","article-title":"Anaphylaxis in America: the prevalence and characteristics of anaphylaxis in the United States","volume":"133","author":"Wood","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2022.10.005_bib3","doi-asserted-by":"crossref","first-page":"AB271","DOI":"10.1016\/j.jaci.2013.12.959","article-title":"Utility of ICD-9-CM codes for identification of allergic drug reactions","volume":"133","author":"Saff","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2022.10.005_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2011.09.018","article-title":"Anaphylaxis in a New York City pediatric emergency department: Triggers, treatments, and outcomes","volume":"129","author":"Huang","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2022.10.005_bib5","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2014.08.018","article-title":"Fatal anaphylaxis in the United States, 1999-2010: Temporal patterns and demographic associations","volume":"134","author":"Jerschow","year":"2014","journal-title":"J\u00a0Allergy Clin Immun"},{"key":"10.1016\/j.iac.2022.10.005_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/ACI.0000000000000722","article-title":"Epidemiology of anaphylaxis","volume":"21","author":"Tanno","year":"2021","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2022.10.005_bib7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaci.2008.10.049","article-title":"Anaphylaxis fatalities and admissions in Australia","volume":"123","author":"Liew","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2022.10.005_bib8","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jaci.2014.10.021","article-title":"Increase in anaphylaxis-related hospitalizations but no increase in fatalities: An analysis of United Kingdom national anaphylaxis data, 1992-2012","volume":"135","author":"Turner","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2022.10.005_bib9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2022.10.005_bib10","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","article-title":"Incidence and preventability of adverse drug events among older persons in the ambulatory setting","volume":"289","author":"Gurwitz","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.iac.2022.10.005_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2042098615615472","article-title":"Predicting risk of adverse drug reactions in older adults","volume":"7","author":"Lavan","year":"2016","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.iac.2022.10.005_bib12","first-page":"69","article-title":"Drug induced hypersensitivity and the HLA Complex","volume":"4","author":"Alfirevic","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.iac.2022.10.005_bib13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaci.2014.05.018","article-title":"Risk factors for severe anaphylaxis in patients receiving anaphylaxis treatment in US emergency departments and hospitals","volume":"134","author":"Clark","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2022.10.005_bib14","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.anai.2017.07.014","article-title":"Risk factors for severe anaphylaxis in the United States","volume":"119","author":"Motosue","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.iac.2022.10.005_bib15","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/all.13380","article-title":"Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry","volume":"73","author":"Worm","year":"2018","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.iac.2022.10.005_bib16","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/j.1399-3038.2011.01200.x","article-title":"Risk factors for severe pediatric food anaphylaxis in Italy","volume":"22","author":"Calvani","year":"2011","journal-title":"Pediatr Allergy Immu"},{"key":"10.1016\/j.iac.2022.10.005_bib17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.anai.2010.03.004","article-title":"Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system","volume":"104","author":"Iribarren","year":"2010","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.iac.2022.10.005_bib18","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.1955.02950270032009","article-title":"Problems of Drug Allergy","volume":"157","author":"Brown","year":"1955","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.iac.2022.10.005_bib19","unstructured":"Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?CFRPart=312&showFR=1. Accessed July 23, 2021."},{"key":"10.1016\/j.iac.2022.10.005_bib20","first-page":"1","article-title":"International drug monitoring: the role of national centres","volume":"498","year":"1972","journal-title":"World Health Organ Tech Rep Ser"},{"key":"10.1016\/j.iac.2022.10.005_bib21","series-title":"Textbook of adverse drug reactions","first-page":"10","article-title":"Pathogenesis of adverse drug reactions","author":"Rawlins","year":"1977"},{"key":"10.1016\/j.iac.2022.10.005_bib22","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.iac.2022.10.005_bib23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/all.12350","article-title":"International Consensus on drug allergy","volume":"69","author":"Demoly","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.iac.2022.10.005_bib24","series-title":"Clinical aspects of immunology","article-title":"The classification of allergic reactions underlying disease","author":"Gell","year":"1963"},{"key":"10.1016\/j.iac.2022.10.005_bib25","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.coi.2003.09.010","article-title":"Mast cell signal transduction from the high-affinity IgE receptor","volume":"15","author":"Siraganian","year":"2003","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.iac.2022.10.005_bib26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2500\/aap.2019.40.4274","article-title":"Classification of hypersensitivity reactions","volume":"40","author":"Dispenza","year":"2019","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"10.1016\/j.iac.2022.10.005_bib27","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.mcna.2010.03.007","article-title":"Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock)","volume":"94","author":"Limsuwan","year":"2010","journal-title":"Med Clin North Am"},{"issue":"4","key":"10.1016\/j.iac.2022.10.005_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1080\/01478885.2020.1804234","article-title":"The road from cytotoxins to immunohistochemistry","volume":"44","author":"Dimenstein","year":"2021","journal-title":"J\u00a0Histotechnol"},{"key":"10.1016\/j.iac.2022.10.005_bib29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2500\/aap.2012.33.3561","article-title":"Chapter 28: classification of hypersensitivity reactions","volume":"33","author":"Uzzaman","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.iac.2022.10.005_bib30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.semarthrit.2015.06.014","article-title":"Rituximab-induced serum sickness: A systematic review","volume":"45","author":"Karmacharya","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.iac.2022.10.005_bib31","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1080\/21645515.2019.1602435","article-title":"The vaccines-associated Arthus reaction","volume":"15","author":"Peng","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.iac.2022.10.005_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-med-050913-022745","article-title":"T\u00a0Cell\u2013Mediated Hypersensitivity Reactions to Drugs","volume":"66","author":"Pavlos","year":"2015","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.iac.2022.10.005_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/tan.13183","article-title":"HLAs: Key regulators of T-cell-mediated drug hypersensitivity","volume":"91","author":"Redwood","year":"2018","journal-title":"HLA"},{"issue":"4","key":"10.1016\/j.iac.2022.10.005_bib34","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.mcna.2010.04.003","article-title":"Drug Hypersensitivity Reactions: Pathomechanism and Clinical Symptoms","volume":"94","author":"Pichler","year":"2010","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.iac.2022.10.005_bib35","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000453265","article-title":"Classification of Drug Hypersensitivity into Allergic, p-i, and Pseudo-Allergic Forms","volume":"171","author":"Pichler","year":"2017","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2022.10.005_bib36","first-page":"1781","article-title":"Adverse drug reactions: types and treatment options","volume":"68","author":"Riedl","year":"2003","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.iac.2022.10.005_bib37","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.jaci.2009.10.028","article-title":"Drug allergy","volume":"125","author":"Khan","year":"2010","journal-title":"J\u00a0Allergy Clin Immun"},{"key":"10.1016\/j.iac.2022.10.005_bib38","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1016\/S0091-6749(97)70128-3","article-title":"Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines","volume":"99","author":"Monroe","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2022.10.005_bib39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.2500\/aap.2012.33.3557","article-title":"Chapter 24: Anaphylaxis","volume":"33","author":"Greenberger","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.iac.2022.10.005_bib40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1182\/asheducation-2009.1.73","article-title":"Drug-induced immune hemolytic anemia","author":"Garratty","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.iac.2022.10.005_bib41","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s002280050272","article-title":"Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy","volume":"52","author":"Pedersen-Bjergaard","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.iac.2022.10.005_bib42","doi-asserted-by":"crossref","first-page":"95","DOI":"10.21307\/immunohematology-2019-103","article-title":"Drug-induced immune neutropenia\/agranulocytosis","volume":"30","author":"Curtis","year":"2014","journal-title":"Immunohematology"},{"issue":"4","key":"10.1016\/j.iac.2022.10.005_bib43","first-page":"240","article-title":"Lupus: an overview of the disease and management options","volume":"37","author":"Maidhof","year":"2012","journal-title":"P T"},{"key":"10.1016\/j.iac.2022.10.005_bib44","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.autrev.2018.03.016","article-title":"Drug-induced lupus: Traditional and new concepts","volume":"17","author":"Vaglio","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.iac.2022.10.005_bib45","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.3390\/ijms22042147","article-title":"Current Perspective Regarding the Immunopathogenesis of Drug-Induced Hypersensitivity Syndrome\/Drug Reaction with Eosinophilia and Systemic Symptoms (DIHS\/DRESS)","volume":"22","author":"Miyagawa","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.iac.2022.10.005_bib46","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.iac.2022.10.005_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2332\/allergolint.55.1","article-title":"Drug-induced Hypersensitivity Syndrome(DIHS): A Reaction Induced by a Complex Interplay among Herpesviruses and Antiviral and Antidrug Immune Responses","volume":"55","author":"Shiohara","year":"2006","journal-title":"Allergol Int"},{"key":"10.1016\/j.iac.2022.10.005_bib48","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2018.08.052","article-title":"Drug-induced hypersensitivity syndrome\/drug reaction with eosinophilia and systemic symptoms severity score: A useful tool for assessing disease severity and predicting fatal cytomegalovirus disease","volume":"80","author":"Mizukawa","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2022.10.005_bib49","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2022.10.005_bib50","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.alit.2019.03.006","article-title":"Drug-induced hypersensitivity syndrome (DiHS)\/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019","volume":"68","author":"Shiohara","year":"2019","journal-title":"Allergol Int"},{"issue":"9","key":"10.1016\/j.iac.2022.10.005_bib51","first-page":"577","article-title":"Drug reaction with eosinophilia and systemic symptoms (DRESS): a complex interaction of drugs, viruses and the immune system","volume":"14","author":"Criado","year":"2012","journal-title":"Isr Med Assoc J"},{"issue":"7","key":"10.1016\/j.iac.2022.10.005_bib52","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.iac.2022.10.005_bib53","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/ijd.14174","article-title":"Prevalence, risk factors, and mortality outcome in the drug reaction with eosinophilia and systemic symptoms patients with cardiac involvement","volume":"57","author":"Intarasupht","year":"2018","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.iac.2022.10.005_bib54","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.iac.2022.10.005_bib55","doi-asserted-by":"crossref","first-page":"131","DOI":"10.4065\/mcp.2009.0379","article-title":"Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic","volume":"85","author":"Wetter","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.iac.2022.10.005_bib56","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1056\/NEJM199411103311906","article-title":"Severe Adverse Cutaneous Reactions to Drugs","volume":"331","author":"Roujeau","year":"1994","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2022.10.005_bib57","first-page":"E6","article-title":"Asboe-Hansen sign in toxic epidermal necrolysis","volume":"103","author":"Dowling","year":"2019","journal-title":"Cutis"},{"key":"10.1016\/j.iac.2022.10.005_bib58","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00417-019-04421-z","article-title":"Ocular manifestations in patients with Stevens\u2013Johnson syndrome in Malawi\u2014review of the literature illustrated by clinical cases","volume":"257","author":"Schwering","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.iac.2022.10.005_bib59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2022.10.005_bib60","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1001\/jamadermatol.2018.5605","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with stevens-johnson syndrome\/toxic epidermal necrolysis\u2014ABCD-10","volume":"155","author":"Noe","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.iac.2022.10.005_bib61","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jamadermatol.2020.3654","article-title":"Assessment and Comparison of Performance of ABCD-10 and SCORTEN in Prognostication of Epidermal Necrolysis","volume":"156","author":"Koh","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.iac.2022.10.005_bib62","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaad.2021.04.082","article-title":"Performance of ABCD-10 and SCORTEN mortality prediction models in a cohort of patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"85","author":"Duplisea","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.iac.2022.10.005_bib63","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/archderm.1991.01680080069004","article-title":"Acute generalized exanthematous pustulosis. Analysis of 63 cases","volume":"127","author":"Roujeau","year":"1991","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.iac.2022.10.005_bib64","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2133.2007.08156.x","article-title":"Risk factors for acute generalized exanthematous pustulosis (AGEP)\u2014results of a multinational case\u2013control study (EuroSCAR)","volume":"157","author":"Sidoroff","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.iac.2022.10.005_bib65","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3390\/ijms17081214","article-title":"Acute generalized exanthematous pustulosis: pathogenesis, genetic background, clinical variants and therapy","volume":"17","author":"Feldmeyer","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.iac.2022.10.005_bib66","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/0002-9343(80)90363-0","article-title":"The problem of \u201cprotopathic bias\u201d in case-control studies","volume":"68","author":"Horwitz","year":"1980","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.iac.2022.10.005_bib67","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.annemergmed.2006.01.018","article-title":"Second symposium on the definition and management of anaphylaxis: summary report--second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"47","author":"Sampson","year":"2006","journal-title":"Ann Emerg Med"},{"issue":"8","key":"10.1016\/j.iac.2022.10.005_bib68","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1111\/j.1398-9995.2008.01733.x","article-title":"World Allergy Organization ad hoc Committee on Epinephrine in A. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization","volume":"63","author":"Kemp","year":"2008","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.iac.2022.10.005_bib69","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1067\/mai.2001.119409","article-title":"Epinephrine absorption in adults: Intramuscular versus subcutaneous injection","volume":"108","author":"Simons","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2022.10.005_bib70","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jaci.2020.01.017","article-title":"Anaphylaxis\u2014a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis","volume":"145","author":"Shaker","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2022.10.005_bib71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/0310057X8601400105","article-title":"Clinical Observations on the Pathophysiology and Treatment of Anaphylactic Cardiovascular Collapse","volume":"14","author":"Fisher","year":"1986","journal-title":"Anaesth Intensive Care"},{"issue":"2","key":"10.1016\/j.iac.2022.10.005_bib72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/WOX.0b013e318211496c","article-title":"World allergy organization guidelines for the assessment and management of anaphylaxis","volume":"4","author":"Simons","year":"2011","journal-title":"World Allergy Organ J"},{"issue":"5","key":"10.1016\/j.iac.2022.10.005_bib73","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2017.05.022","article-title":"Do Corticosteroids Prevent Biphasic Anaphylaxis?","volume":"5","author":"Alqurashi","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.iac.2022.10.005_bib74","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.resuscitation.2021.04.010","article-title":"Evidence update for the treatment of anaphylaxis","volume":"163","author":"Dodd","year":"2021","journal-title":"Resuscitation"},{"issue":"6","key":"10.1016\/j.iac.2022.10.005_bib75","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMra066469","article-title":"Drug-Induced Immune Thrombocytopenia","volume":"357","author":"Aster","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.iac.2022.10.005_bib76","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1517\/14740338.7.4.481","article-title":"Recognition and management of drug-induced blood cytopenias: the example of drug-induced acute neutropenia and agranulocytosis","volume":"7","author":"Andr\u00e8s","year":"2008","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.iac.2022.10.005_bib77","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-017-8654-z","article-title":"Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis","volume":"54","author":"Lerch","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"10.1016\/j.iac.2022.10.005_bib78","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2015.08.033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis treatments: An Internet survey","volume":"74","author":"Curtis","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2022.10.005_bib79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A\u00a0Multicenter Review of Toxic Epidermal Necrolysis Treated in U.S. Burn Centers at the End of the Twentieth Century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J\u00a0Burn Care Rehabil"},{"issue":"6","key":"10.1016\/j.iac.2022.10.005_bib80","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.anai.2020.03.012","article-title":"Children with reported penicillin allergy: Public health impact and safety of delabeling","volume":"124","author":"Vyles","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.iac.2022.10.005_bib81","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/QCO.0000000000000006","article-title":"Antimicrobial stewardship\u2019s new weapon? A review of antibiotic allergy and pathways to \u2018de-labeling","volume":"26","author":"Trubiano","year":"2013","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"10.1016\/j.iac.2022.10.005_bib82","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaip.2013.02.002","article-title":"Safely Diagnosing Clinically Significant Penicillin Allergy Using Only Penicilloyl-Poly-Lysine, Penicillin, and Oral Amoxicillin","volume":"1","author":"Macy","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"1","key":"10.1016\/j.iac.2022.10.005_bib83","doi-asserted-by":"crossref","first-page":"100093","DOI":"10.1016\/j.waojou.2019.100093","article-title":"Beta-lactam antibiotic test doses in the emergency department","volume":"13","author":"Maguire","year":"2020","journal-title":"World Allergy Organ J"},{"issue":"6","key":"10.1016\/j.iac.2022.10.005_bib84","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/cid\/ciaa194","article-title":"Penicillin Allergy Testing Is Cost-Saving: An Economic Evaluation Study","volume":"72","author":"Sousa-Pinto","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985612200902X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985612200902X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:52:41Z","timestamp":1760179961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985612200902X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S088985612200902X"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2022.10.005","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Hypersensitivity Reactions","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2022.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}